LHX9 Inhibitors
Chemical inhibitors classified as LHX9 inhibitors encompass a diverse set of compounds that interact with various signaling pathways that potentially modulate the activity, expression, or stability of the LHX9 protein. These compounds do not bind directly to the LHX9 protein but instead exert their effects on upstream or downstream regulatory pathways that can influence LHX9 indirectly. The chemical compounds listed have diverse structures and are used as tools to interrogate biological pathways, including but not limited to Hedgehog, PI3K/Akt, MAPK/ERK, mTOR, HIF, Notch, TGF-beta/SMAD, Wnt/beta-catenin, ROCK, and JNK. Each of these pathways can play a role in cellular processes such as growth, differentiation, or development where LHX9 is known to be involved.
The specific inhibitors mentioned target key enzymes or components within these pathways, thereby altering the signaling cascade. Inhibition of these pathways can lead to changes in gene expression profiles, including those of homeobox genes like LHX9, thus impacting their ultimate function in the cell. It is through these indirect mechanisms that the listed compounds can modulate LHX9 activity within various cellular contexts. These inhibitors serve as valuable research tools to dissect the complex signaling networks within cells and to understand how perturbations in these pathways can lead to varied biological outcomes, providing insight into the multi-faceted roles of homeobox proteins such as LHX9.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine is an inhibitor of the Hedgehog (Hh) signaling pathway, which can regulate genes involved in embryonic development, potentially affecting LHX9 expression indirectly. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor that can alter the PI3K/Akt pathway, potentially influencing LHX9's post-translational modification or its stability. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can affect the PI3K/AKT/mTOR pathway, potentially impacting LHX9 activity indirectly by modulating cellular growth signals. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
Chetomin disrupts the hypoxia-inducible factor (HIF) pathway, which could influence LHX9 expression in a low-oxygen environment. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a gamma-secretase inhibitor which can modulate the Notch signaling pathway, potentially altering LHX9 activity as part of the developmental regulatory network. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the TGF-beta receptor, impacting the SMAD pathway, which may intersect with LHX9's role in development. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MAP kinase inhibitor which can affect the MAPK/ERK pathway and possibly the regulation of LHX9 indirectly. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV-939 inhibits the Wnt/beta-catenin pathway by stabilizing Axin, which can indirectly affect LHX9's regulation due to the Wnt pathway's involvement in development. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor which may impact actin cytoskeleton organization, potentially affecting LHX9's cellular context and influencing its expression or function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor, affecting various signaling pathways including those that may regulate LHX9. | ||||||